Ella Mae Joy S. Sira
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ella Mae Joy S. Sira has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Fredmoore Legaspi Orosco
Industrial Technology Development Institute, Department of Science and Technology, Taguig, Philippines
6 shared publications - Edward Coralde Banico
Virology and Vaccine Research Program, Department of Science and Technology, Industrial Technology Development Institute, Taguig City, Philippines
4 shared publications - Lauren Emily Fajardo
Virology and Vaccine Research Program, Department of Science and Technology, Industrial Technology Development Institute, Taguig City, Philippines
4 shared publications - Nyzar Mabeth Obenio Odchimar
Virology and Vaccine Research Program, Department of Science and Technology, Industrial Technology Development Institute, Taguig City, Philippines
3 shared publications - Alea Maurice Simbulan1 shared publication
Edward C. Banico
1 shared publication
Latest Publications
- 1 August 2025
- Published by Springer Nature in Network Modeling Analysis in Health Informatics and Bioinformatics
- Vol. 14 (1) , 1-17
Reverse vaccinology-aided design of an epitope-based subunit vaccine against classical swine fever virus
- 1 August 2025
- Published by Springer Nature in Network Modeling Analysis in Health Informatics and Bioinformatics
- Vol. 14 (1) , 1-17
Reverse vaccinology-aided design of an epitope-based subunit vaccine against classical swine fever virus
- 30 April 2025
- Published by Philippine-American Academy of Science and Engineering in SciEnggJ
- Vol. 18 (1) , 82-101
n silico approach for designing a pan-proteomic and pan-genotypic hepatitis C virus multi-epitope subunit vaccine
Hepatitis C Virus (HCV) is the most infectious hepatitis virus and the leading cause of liver-related mortality. The lack of a vaccine, combined with HCV’s hypervariability, contributes to this global health concern; thus, there is an urgent need for a potent, cross-protective vaccine. With the aid of computational vaccinology, we aimed to design and evaluate multi-epitope vaccines based on highly conserved epitopes from multiple proteins across 8 recognized HCV genotypes and 47 subtypes. The designed HCV vaccine constructs (VC) are composed of antigenic, non-allergenic, non-toxic, non-human homologues, and conserved epitopes within the structural and non-structural HCV proteins, linked with proper adjuvants and linkers. The final HCV VC had an instability index of 33.69. Tertiary structure validation of the modelled HCV VC revealed a high-quality protein. Molecular docking, molecular dynamic simulations, and Molecular Mechanics/Poisson–Boltzmann Surface Area (MM/PBSA) and General Born Surface Area (MM/GBSA) calculations demonstrated a strong and stable binding interaction between the HCV VC and immune receptors (TLR2, 3, and 4). The final HCV VC-TLR3 is the best docking complex (-226.61 kcal/mol) with a highly stable binding affinity in the entire 200 ns molecular dynamics simulation. Notably, immune simulation revealed that HCV VC elicited a high antibody level and stronger IFN-ɣ and IL-2 levels compared to reference studies. This study designed a novel multi-epitope HCV VC that could provide a stronger immune response and cross-protection against hypervariable HCV that requires further in vitro validation.
- 30 April 2025
- Published by Philippine-American Academy of Science and Engineering in SciEnggJ
- Vol. 18 (1) , 82-101
n silico approach for designing a pan-proteomic and pan-genotypic hepatitis C virus multi-epitope subunit vaccine
Hepatitis C Virus (HCV) is the most infectious hepatitis virus and the leading cause of liver-related mortality. The lack of a vaccine, combined with HCV’s hypervariability, contributes to this global health concern; thus, there is an urgent need for a potent, cross-protective vaccine. With the aid of computational vaccinology, we aimed to design and evaluate multi-epitope vaccines based on highly conserved epitopes from multiple proteins across 8 recognized HCV genotypes and 47 subtypes. The designed HCV vaccine constructs (VC) are composed of antigenic, non-allergenic, non-toxic, non-human homologues, and conserved epitopes within the structural and non-structural HCV proteins, linked with proper adjuvants and linkers. The final HCV VC had an instability index of 33.69. Tertiary structure validation of the modelled HCV VC revealed a high-quality protein. Molecular docking, molecular dynamic simulations, and Molecular Mechanics/Poisson–Boltzmann Surface Area (MM/PBSA) and General Born Surface Area (MM/GBSA) calculations demonstrated a strong and stable binding interaction between the HCV VC and immune receptors (TLR2, 3, and 4). The final HCV VC-TLR3 is the best docking complex (-226.61 kcal/mol) with a highly stable binding affinity in the entire 200 ns molecular dynamics simulation. Notably, immune simulation revealed that HCV VC elicited a high antibody level and stronger IFN-ɣ and IL-2 levels compared to reference studies. This study designed a novel multi-epitope HCV VC that could provide a stronger immune response and cross-protection against hypervariable HCV that requires further in vitro validation.
- Open Access
- 6 April 2025
- Published by Maad Rayan Publishing Company in BioImpacts
- Vol. 15 (1) , 30778
Immunoinformatics design of an mRNA vaccine against classical swine fever virus using conserved E2 protein and NS3 T-lymphocyte epitopes
Introduction: The classical swine fever virus (CSFV) causes significant economic losses in the livestock industry. While the existing E2 marker vaccine offers protection against infections, it is characterized by delayed immunity and reduced effectiveness over time. Optimizing the existing vaccine is crucial to better control CSFV outbreaks worldwide. This study aimed to improve the existing E2 marker vaccine for CSFV by integrating NS3 T lymphocyte-inducing epitopes into the conserved E2 protein sequence and using mRNA technology for vaccine delivery. Methods: The design and evaluation of the vaccine were carried out exclusively through in silico methods. T lymphocyte epitopes were identified from the CSFV NS3 protein using multiple epitope prediction tools. A vaccine construct was formed after linking the predicted NS3 epitopes, E2 protein, and an immunogenic adjuvant. Molecular docking and dynamics simulations were performed to analyze the interaction between the adjuvant used and its immune receptor. Signal peptides were incorporated into the design, and mRNA sequences with varying codon usage biases were generated using LinearDesign. The mRNA sequence with minimum free energy (MFE) and codon adaptation index (CAI) closest to the controls was selected as the final design. Results: Twenty epitopes with high binding affinity to major histocompatibility complexes (MHCs) were identified from the CSFV NS3 protein. The vaccine construct with swine CD154 adjuvant demonstrated high antigenicity, making it the optimal choice for the final vaccine design. Molecular docking and dynamics simulations confirmed the adjuvant's strong affinity and stable interaction with its canonical receptor, swine CD40. Moreover, the final vaccine design exhibited higher populations of lymphocytes and antibodies compared to the components of the commercialized E2 marker vaccine in immune simulation. The final mRNA vaccine sequence exhibited a higher MFE and CAI than the two licensed mRNA vaccine controls. Conclusion: The mRNA vaccine designed in this study serves as a potential CSFV vaccine candidate. In vivo and in vitro validation is needed to confirm its efficacy.
- 6 April 2025
- Published by Maad Rayan Publishing Company in BioImpacts
- Vol. 15 (1) , 30778
Open AccessImmunoinformatics design of an mRNA vaccine against classical swine fever virus using conserved E2 protein and NS3 T-lymphocyte epitopes
Introduction: The classical swine fever virus (CSFV) causes significant economic losses in the livestock industry. While the existing E2 marker vaccine offers protection against infections, it is characterized by delayed immunity and reduced effectiveness over time. Optimizing the existing vaccine is crucial to better control CSFV outbreaks worldwide. This study aimed to improve the existing E2 marker vaccine for CSFV by integrating NS3 T lymphocyte-inducing epitopes into the conserved E2 protein sequence and using mRNA technology for vaccine delivery. Methods: The design and evaluation of the vaccine were carried out exclusively through in silico methods. T lymphocyte epitopes were identified from the CSFV NS3 protein using multiple epitope prediction tools. A vaccine construct was formed after linking the predicted NS3 epitopes, E2 protein, and an immunogenic adjuvant. Molecular docking and dynamics simulations were performed to analyze the interaction between the adjuvant used and its immune receptor. Signal peptides were incorporated into the design, and mRNA sequences with varying codon usage biases were generated using LinearDesign. The mRNA sequence with minimum free energy (MFE) and codon adaptation index (CAI) closest to the controls was selected as the final design. Results: Twenty epitopes with high binding affinity to major histocompatibility complexes (MHCs) were identified from the CSFV NS3 protein. The vaccine construct with swine CD154 adjuvant demonstrated high antigenicity, making it the optimal choice for the final vaccine design. Molecular docking and dynamics simulations confirmed the adjuvant's strong affinity and stable interaction with its canonical receptor, swine CD40. Moreover, the final vaccine design exhibited higher populations of lymphocytes and antibodies compared to the components of the commercialized E2 marker vaccine in immune simulation. The final mRNA vaccine sequence exhibited a higher MFE and CAI than the two licensed mRNA vaccine controls. Conclusion: The mRNA vaccine designed in this study serves as a potential CSFV vaccine candidate. In vivo and in vitro validation is needed to confirm its efficacy.
- Open Access
- 3 January 2025
- Published by Wiley in Veterinary Medicine International
- Vol. 2025 (1) , 2638167
Design of a Multiepitope Pan‐Proteomic mRNA Vaccine Construct Against African Swine Fever Virus: A Reverse Vaccinology Approach
African swine fever (ASF), caused by African swine fever virus (ASFV), is a highly contagious disease with devastating effects on the global pig industry. This warrants the development of effective control strategies, such as vaccines. However, previously developed inactivated vaccines have proven ineffective, while live‐attenuated vaccines carry inherent safety risks. The use of mRNA vaccines eliminates these risks offering a safe, cost‐effective, and efficient vaccine strategy against ASFV. In this study, a reverse vaccinology approach was used to design a multiepitope pan‐proteomic mRNA vaccine against ASFV. Various bioinformatics tools were employed to predict epitopes for cytotoxic T lymphocytes, helper T lymphocytes, and B lymphocytes. A 50S ribosomal L7/L12 protein adjuvant, 5′ cap, poly(A) tail, signal peptide, and MHC‐I‐targeting domain were incorporated into the design using appropriate linkers to increase immunogenicity, stability, and recognition efficiency. The physicochemical properties of the final construct were evaluated, and docking analyses were done with Toll‐like receptors (TLRs) 3, 4, and 7 to evaluate binding affinity. A molecular dynamics simulation was then performed to determine binding stability, while immune simulations evaluated host’s immune response. Based on 100 ASFV proteomes, six epitopes that induce cytotoxic T‐cell responses, five epitopes that induce helper T‐cell responses, and four epitopes that induce antibody production were predicted. The designed vaccine construct was found to be nonallergenic, antigenic, and stable when bound to TLR4 while the binding pocket analyses of the vaccine construct to TLR3 and TLR7 indicate high translation efficiency. Immune simulations demonstrated successful induction of immune responses and generation of antigen‐specific memory cells. In conclusion, this study introduces an mRNA vaccine construct as a potential disease control strategy against ASF for in vitro confirmation.
- 3 January 2025
- Published by Wiley in Veterinary Medicine International
- Vol. 2025 (1) , 2638167
Open AccessDesign of a Multiepitope Pan‐Proteomic mRNA Vaccine Construct Against African Swine Fever Virus: A Reverse Vaccinology Approach
African swine fever (ASF), caused by African swine fever virus (ASFV), is a highly contagious disease with devastating effects on the global pig industry. This warrants the development of effective control strategies, such as vaccines. However, previously developed inactivated vaccines have proven ineffective, while live‐attenuated vaccines carry inherent safety risks. The use of mRNA vaccines eliminates these risks offering a safe, cost‐effective, and efficient vaccine strategy against ASFV. In this study, a reverse vaccinology approach was used to design a multiepitope pan‐proteomic mRNA vaccine against ASFV. Various bioinformatics tools were employed to predict epitopes for cytotoxic T lymphocytes, helper T lymphocytes, and B lymphocytes. A 50S ribosomal L7/L12 protein adjuvant, 5′ cap, poly(A) tail, signal peptide, and MHC‐I‐targeting domain were incorporated into the design using appropriate linkers to increase immunogenicity, stability, and recognition efficiency. The physicochemical properties of the final construct were evaluated, and docking analyses were done with Toll‐like receptors (TLRs) 3, 4, and 7 to evaluate binding affinity. A molecular dynamics simulation was then performed to determine binding stability, while immune simulations evaluated host’s immune response. Based on 100 ASFV proteomes, six epitopes that induce cytotoxic T‐cell responses, five epitopes that induce helper T‐cell responses, and four epitopes that induce antibody production were predicted. The designed vaccine construct was found to be nonallergenic, antigenic, and stable when bound to TLR4 while the binding pocket analyses of the vaccine construct to TLR3 and TLR7 indicate high translation efficiency. Immune simulations demonstrated successful induction of immune responses and generation of antigen‐specific memory cells. In conclusion, this study introduces an mRNA vaccine construct as a potential disease control strategy against ASF for in vitro confirmation.
- Open Access
- 4 November 2024
- Published by Veterinary World in International Journal of One Health
Bridging One Health: Computational design of a multi-epitope messenger RNA vaccine for cross-species immunization against Nipah virus
Background and Aim: Nipah virus (NiV) poses a threat to human and animal health, particularly swine, which serve as primary vectors for human transmission. Despite its severe risks, no NiV vaccine currently exists for humans or animal hosts; thus, innovative vaccine development approaches that address cross-species transmission are required. This study was computationally designed to evaluate a multi-epitope messenger RNA (mRNA) vaccine targeting NiV for human and swine immunization. Materials and Methods: B and T lymphocyte epitopes were identified from NiV structural proteins using multiple epitope prediction tools. All epitopes were linked to form a multi-epitope construct, and various adjuvant combinations were analyzed for physicochemical properties and immune simulation. Molecular docking and dynamics were employed to visualize the construct’s interaction with a host immune receptor. Signal peptides were added to the construct, and mRNA sequences were generated using LinearDesign. The minimum free energies (MFEs) and codon adaptation indices (CAI) were used to select the final mRNA sequence of the vaccine construct. Results: Computational tools predicted 10 epitopes within NiV structural proteins that can be recognized by human and swine immune receptors. The construct with β-defensin 2 adjuvant was selected as the final immunogenic region after showing favorable immunogenicity profiles and physicochemical properties. The final vaccine sequence had higher MFE and CAI compared to the BioNTech/Pfizer BNT162b2 and Moderna mRNA-1273 vaccines. Conclusion: The multi-epitope mRNA vaccine designed in this study shows promising results as a potential NiV vaccine candidate. Further in vivo and in vitro studies are required to confirm the efficacy. Keywords: computational design, cross-species immunization, messenger RNA vaccine, multi-epitope, Nipah virus.
- 4 November 2024
- Published by Veterinary World in International Journal of One Health
Open AccessBridging One Health: Computational design of a multi-epitope messenger RNA vaccine for cross-species immunization against Nipah virus
Background and Aim: Nipah virus (NiV) poses a threat to human and animal health, particularly swine, which serve as primary vectors for human transmission. Despite its severe risks, no NiV vaccine currently exists for humans or animal hosts; thus, innovative vaccine development approaches that address cross-species transmission are required. This study was computationally designed to evaluate a multi-epitope messenger RNA (mRNA) vaccine targeting NiV for human and swine immunization. Materials and Methods: B and T lymphocyte epitopes were identified from NiV structural proteins using multiple epitope prediction tools. All epitopes were linked to form a multi-epitope construct, and various adjuvant combinations were analyzed for physicochemical properties and immune simulation. Molecular docking and dynamics were employed to visualize the construct’s interaction with a host immune receptor. Signal peptides were added to the construct, and mRNA sequences were generated using LinearDesign. The minimum free energies (MFEs) and codon adaptation indices (CAI) were used to select the final mRNA sequence of the vaccine construct. Results: Computational tools predicted 10 epitopes within NiV structural proteins that can be recognized by human and swine immune receptors. The construct with β-defensin 2 adjuvant was selected as the final immunogenic region after showing favorable immunogenicity profiles and physicochemical properties. The final vaccine sequence had higher MFE and CAI compared to the BioNTech/Pfizer BNT162b2 and Moderna mRNA-1273 vaccines. Conclusion: The multi-epitope mRNA vaccine designed in this study shows promising results as a potential NiV vaccine candidate. Further in vivo and in vitro studies are required to confirm the efficacy. Keywords: computational design, cross-species immunization, messenger RNA vaccine, multi-epitope, Nipah virus.